Trial Profile

First multi-centre, randomized, vehicle-controlled, double-blind, parallel group pivotal phase 3 trial of an ultra-potent topical corticosteroid product being developed for the treatment of plaque psoriasis using the Company's patented Multiplexed Molecular Penetration Enhancer ("MMPE™") technology

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Feb 2020 New trial record
11 Feb 2020 Results presented in a Crescita Therapeutics Media Release.
11 Feb 2020 According to a Crescita Therapeutics media release, primary end point ( Investigator's Global Assessment (IGA's) treatment success at the end of study, has been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com